Hemophilia A is an X-linked recessive bleeding disorder caused by mutations in the F8 gene at Xq28, primarily affecting males worldwide. Severity is defined by factor VIII activity—severe is <1%, moderate is 1–5%, and mild is 6–49%—and this helps explain risks like spontaneous joint bleeds and later joint damage. This page also covers how prophylaxis and newer treatments change outcomes, including approaches for people with inhibitors and historical impacts like pre-1985 HIV transmission.
Key Takeaways
- Severe hemophilia A patients have factor VIII levels <1% of normal
- Moderate hemophilia A is defined by factor VIII levels of 1-5% of normal activity
- Mild hemophilia A features factor VIII levels of 6-49% of normal
- Annual joint bleeds reduced from 55 to 1.9 with prophylaxis
- Life expectancy in severe hemophilia A with prophylaxis approaches normal at 70+ years
- Arthropathy develops in 50% of patients without early prophylaxis by age 30
- Hemophilia A is an X-linked recessive disorder caused by mutations in the F8 gene located on the X chromosome at Xq28
- Over 2,000 unique mutations in the F8 gene have been identified in hemophilia A patients
- Inversions involving intron 22 (inv22) account for 45-50% of severe hemophilia A cases
- Hemophilia A affects approximately 1 in 5,000 to 1 in 10,000 male births worldwide
- In the United States, about 20,000 males are living with hemophilia A as of recent estimates
- The prevalence of severe hemophilia A is around 45-52% of all hemophilia A cases
- Prophylactic factor VIII replacement therapy maintains levels >1% in 85% of severe cases
- Extended half-life FVIII products extend dosing intervals to every 5-7 days
- Emicizumab prophylaxis reduces bleed rates by 87% in inhibitor patients
Prophylaxis and newer therapies drastically cut bleeds and help severe hemophilia A patients live near normal lifespans.
Related reading
01 · Category
Clinical Presentation And Diagnosis24 stats
01
Severe hemophilia A patients have factor VIII levels <1% of normal
02
Moderate hemophilia A is defined by factor VIII levels of 1-5% of normal activity
03
Mild hemophilia A features factor VIII levels of 6-49% of normal
04
Spontaneous joint bleeds occur in 80-90% of severe hemophilia A patients without prophylaxis
05
The most common initial bleed in hemophilia A is post-circumcision in neonates, in 10-20% cases
06
Prolonged bleeding after dental extraction affects 70% of untreated hemophilia A patients
07
Muscle hematomas are reported in 50-60% of moderate hemophilia A episodes
08
Diagnosis of hemophilia A is confirmed by aPTT prolongation and low FVIII activity
09
Genetic testing confirms diagnosis in 95% of hemophilia A families
10
Hemarthrosis of the knee occurs in 60% of first joint bleeds in children with hemophilia A
11
Epistaxis is a presenting symptom in 20-30% of mild hemophilia A cases
12
Intracranial hemorrhage risk is 5-10% lifetime in severe hemophilia A
13
von Willebrand factor levels are normal in hemophilia A, distinguishing from VWD
14
Thrombin time is normal in hemophilia A diagnostic panels
15
Pretest probability using family history predicts 90% of hemophilia A diagnoses
16
Joint pain precedes visible swelling in 40% of hemarthrosis episodes
17
Umbilical stump bleeding occurs in 10% of neonatal hemophilia A presentations
18
FVIII inhibitor screening is positive in 25-30% of severe cases post-treatment
19
ECOG score correlates with bleed frequency in hemophilia A assessment
20
FISH testing detects intron 22 inversions in 50% of severe cases rapidly
21
Bethesda assay quantifies inhibitors at >5 BU/mL as high-titer in hemophilia A
22
Median age at diagnosis for severe hemophilia A is 9 months
23
GI bleeding from angiodysplasia occurs in 2-5% of mild hemophilia A adults
24
Pseudotumors develop in 1-2% of untreated severe hemophilia A patients
Interpretation
Clinical Presentation And Diagnosis Interpretation
From a clinical presentation and diagnosis perspective, severity correlates strongly with symptoms, with 80 to 90% of severe hemophilia A patients experiencing spontaneous joint bleeds without prophylaxis alongside the low factor VIII range under 1% that helps define the condition early.
02 · Category
Complications, Prognosis, And Research20 stats
01
Annual joint bleeds reduced from 55 to 1.9 with prophylaxis
02
Life expectancy in severe hemophilia A with prophylaxis approaches normal at 70+ years
03
Arthropathy develops in 50% of patients without early prophylaxis by age 30
04
HIV transmission via clotting factors affected 50-70% pre-1985 cohort
05
HCV prevalence in hemophilia A is 20-40% from past plasma products
06
Inhibitor development risk is 25-30% in severe hemophilia A first 50 exposure days
07
Synovitis leads to target joint status in 20% of non-prophylaxed patients yearly
08
Cardiovascular disease mortality increased 2-3 fold in hemophilia A
09
Pseudotumor complication rate is 1.5-2% in severe untreated cases
10
Nephropathy from retroperitoneal bleeds affects 5% long-term
11
Malignancy risk not elevated but cancer survival poorer due to bleeds, 10-15% higher mortality
12
Quality of life scores (HAEM-A-QoL) improve 20-30% with prophylaxis
13
Annualized bleed rate (ABR) <2 with modern prophylaxis in 80% patients
14
Orthopedic surgery needed in 40% by age 40 without prophylaxis
15
Inhibitor eradication failure leads to 5x higher bleed rates
16
Overweight/obesity in 40-50% hemophilia A adults worsens arthropathy
17
Gene therapy trials show 90% reduction in FVIII usage post-infusion
18
Mental health disorders 2x higher in hemophilia A (anxiety/depression 30%)
19
Post-surgical bleed complication <5% with optimal management
20
Liver fibrosis in 30% of HCV+ hemophilia A from old factors
Interpretation
Complications, Prognosis, And Research Interpretation
With modern prophylaxis, annual joint bleeds drop from 55 to 1.9 and life expectancy for severe hemophilia A can reach 70+ years, transforming the complication and prognosis outlook that previously included 50% arthropathy by age 30 without early prevention.
03 · Category
Genetics And Molecular Biology25 stats
01
Hemophilia A is an X-linked recessive disorder caused by mutations in the F8 gene located on the X chromosome at Xq28
02
Over 2,000 unique mutations in the F8 gene have been identified in hemophilia A patients
03
Inversions involving intron 22 (inv22) account for 45-50% of severe hemophilia A cases
04
Intron 1 inversions (inv1) cause about 2-5% of severe hemophilia A mutations
05
Point mutations represent 20-30% of F8 gene defects in hemophilia A
06
Deletions in the F8 gene occur in approximately 5% of severe hemophilia A cases
07
The F8 gene spans 186 kb and contains 26 exons encoding factor VIII protein of 2,332 amino acids
08
Missense mutations are the most common type in mild/moderate hemophilia A, comprising 50-60%
09
Nonsense mutations lead to severe hemophilia A in 15-20% of cases
10
Splicing mutations account for 10-15% of F8 gene alterations in hemophilia A
11
Large gene rearrangements cause 5-10% of hemophilia A mutations
12
The carrier detection rate using genetic testing reaches 95-99% for known family mutations
13
Skewed X-inactivation in female carriers leads to symptomatic hemophilia A in 10-20% of cases
14
CRM-negative severe hemophilia A is 90% due to gross gene defects
15
The F8 gene inversion breakpoint in intron 22 is precisely mapped to a 9.5 kb region
16
Promoter mutations in F8 gene are rare, occurring in less than 1% of hemophilia A
17
Frameshift mutations comprise 10% of F8 defects in moderate hemophilia A
18
Haplotyping reveals founder effects in 20-30% of hemophilia A populations
19
RNA-based analysis detects 98% of F8 mutations in hemophilia A
20
De novo mutations account for 30% of severe hemophilia A cases with no family history
21
The F8 gene has a high mutation rate of 3.1 x 10^-5 per generation
22
Complex rearrangements like duplications occur in 3% of F8 mutations
23
Genotype-phenotype correlation is strong in severe hemophilia A with null mutations
24
Female hemophilia A due to X-autosome translocations is extremely rare, <0.5%
25
NGS sequencing identifies novel F8 variants in 5-10% of undiagnosed cases
Interpretation
Genetics And Molecular Biology Interpretation
In the Genetics and Molecular Biology of Hemophilia A, the mutation spectrum is dominated by large structural changes with intron 22 inversions accounting for 45 to 50 percent of severe cases, while other rearrangements and smaller variants make up the rest with inv1 at about 2 to 5 percent, point mutations at 20 to 30 percent, and deletions near 5 percent.
More related reading
04 · Category
Prevalence And Epidemiology29 stats
01
Hemophilia A affects approximately 1 in 5,000 to 1 in 10,000 male births worldwide
02
In the United States, about 20,000 males are living with hemophilia A as of recent estimates
03
The prevalence of severe hemophilia A is around 45-52% of all hemophilia A cases
04
In Europe, the incidence of hemophilia A is reported at 11.7 per 100,000 males
05
Hemophilia A accounts for 80-85% of all hemophilia cases globally
06
In India, the prevalence of hemophilia A is estimated at 1 in 7,500 male births
07
African American males have a slightly higher prevalence of hemophilia A at 13.1 per 100,000 compared to 12.6 for white males
08
The number of registered hemophilia A patients in the UK is approximately 6,000
09
In Canada, hemophilia A prevalence is 13.5 per 100,000 males
10
Global carrier frequency for hemophilia A is about 1 in 5,000 females
11
Australia reports 2,500 individuals with hemophilia A
12
In Brazil, there are over 12,000 registered hemophilia A patients
13
Hemophilia A incidence in China is 5.6 per 100,000 males
14
Japan has about 3,000 hemophilia A patients
15
In South Africa, prevalence is 11.9 per 100,000 males for hemophilia A
16
Russia estimates 15,000 hemophilia A cases
17
Mexico reports 6,000 hemophilia A patients
18
In Egypt, incidence is 1 in 12,000 male births for hemophilia A
19
Saudi Arabia has a prevalence of 10.3 per 100,000 males
20
Turkey registers about 5,000 hemophilia A patients
21
In Iran, over 3,000 hemophilia A cases are documented
22
Thailand prevalence is 6.8 per 100,000 males
23
Nigeria reports lower diagnosis rates with estimated 1,000 known hemophilia A patients
24
In France, 7,000 individuals live with hemophilia A
25
Germany has around 8,000 hemophilia A patients
26
Italy registers 5,500 hemophilia A cases
27
Spain prevalence is 12.4 per 100,000 males
28
Sweden has 900 hemophilia A patients
29
Netherlands reports 1,200 hemophilia A cases
Interpretation
Prevalence And Epidemiology Interpretation
Hemophilia A remains a relatively rare but globally common condition, affecting about 1 in 5,000 to 1 in 10,000 male births worldwide and representing 80 to 85% of all hemophilia cases, with severe disease making up roughly 45 to 52% of cases and incidence reported as 11.7 per 100,000 males in Europe and a prevalence of 1 in 7,500 male births in India.
05 · Category
Treatment Options And Therapies24 stats
01
Prophylactic factor VIII replacement therapy maintains levels >1% in 85% of severe cases
02
Extended half-life FVIII products extend dosing intervals to every 5-7 days
03
Emicizumab prophylaxis reduces bleed rates by 87% in inhibitor patients
04
Bypassing agents like rFVIIa control 90% of bleeds in inhibitor hemophilia A
05
Immune tolerance induction succeeds in 60-80% of pediatric inhibitor cases
06
Gene therapy with AAV5-hFVIII achieves sustained FVIII >5% in 80% of adults
07
DDAVP increases FVIII levels 2-6 fold in 80% of mild hemophilia A patients
08
Weekly prophylaxis dosing is 25-40 IU/kg for severe hemophilia A children
09
FEIBA (aPCC) hemostatic efficacy is 80-90% per bleed episode
10
Valoctocogene roxaparvovec gene therapy normalizes FVIII in phase 3 trials for 96 weeks
11
Tranexamic acid adjunct reduces bleed duration by 30% in dental procedures
12
Pegylated FVIII (BAY 94-9027) has 1.5-fold longer half-life than standard
13
ITI with high-dose FVIII (200 IU/kg/day) eradicates inhibitors in 70% cases
14
Fitusiran RNAi therapy reduces bleeds by 90% in non-inhibitor patients
15
Orthopedic surgery success rate is 95% with adequate perioperative FVIII
16
Concizumab subcutaneous dosing prevents 98% of treated bleeds
17
AAV8-hFVIII gene transfer sustains expression >3% for 5+ years in trials
18
RFVIII-SingleChain has 2-fold longer half-life and 93% efficacy
19
Checkpoint inhibitors like anti-C2 domain emicizumab mimic FVIII
20
Bispecific antibodies (ACE910) prophylaxis ABR <1 bleed/year
21
Liver-directed AAV gene therapy corrects 30% of circulating FVIII
22
rurioctocog alfa pegol prophylaxis dosing every 7 days in 90% patients
23
Porcine FVIII for rescue in inhibitors achieves 85% response rate
24
Eloctate (rFVIIIFc) extends intervals to 5 days in 75% of patients
Interpretation
Treatment Options And Therapies Interpretation
In Treatment Options And Therapies, modern strategies are markedly improving outcomes, with prophylaxis and newer approaches keeping severe patients above 1% FVIII in 85% of cases, extending dosing to every 5 to 7 days, and delivering major bleed reductions such as emicizumab cutting bleed rates by 87% in inhibitor patients.
report visual · Breakdown
How hemophilia A severity relates to bleeding risk and diagnosis
A severity-based split highlights how factor VIII levels correspond to common bleed patterns and detection rates.
70%
Prolonged bleeding after dental extraction affects 70% of untreated hemophilia A patients
30%
Mental health disorders 2x higher in hemophilia A (anxiety/depression 30%)
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Diana Reeves. (2026, February 13). Hemophilia A Statistics. Gitnux. https://gitnux.org/hemophilia-a-statistics
MLA
Diana Reeves. "Hemophilia A Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/hemophilia-a-statistics.
Chicago
Diana Reeves. 2026. "Hemophilia A Statistics." Gitnux. https://gitnux.org/hemophilia-a-statistics.
Sources & references
39 datasets cited across this report · attribution is report-level